Prior authorization requirement for Xbryk and Ospomyv (medical benefit)
Adds a prior authorization requirement for most Blue Cross Blue Shield of Michigan and Blue Care Network commercial (group and individual) members for Xbryk and Ospomyv administered under the medical benefit, and describes how providers should submit requests and check group participation.
Prior authorization requirement added for Xbryk and Ospomyv (denosumab-dssb) for most commercial members effective Feb. 28, 2025.
Where to Find Prior Authorization Criteria
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.